Susquehanna International Group’s Compass Therapeutics CMPX Stock Holding History
Bought
Maintained
Sold
Other funds holding CMPX
TCM
O
SCM
ES
VC
PAI
Susquehanna International Group's CMPX Position: Q2 2026 in Review
Susquehanna International Group increased its Compass Therapeutics (CMPX) stake by 96% in Q2 2026, buying an estimated $447K and bringing the position to 308,295 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #9198.
Susquehanna International Group first reported a position in CMPX in Q3 2022 and has held it in 14 quarters since. The position peaked at $2.56M in Q1 2023. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.
- Susquehanna International Group held 308,295 shares of Compass Therapeutics worth $675K as of Q2 2026.
- Susquehanna International Group bought 151,270 Compass Therapeutics shares in Q2 2026, an estimated $447K.
- Compass Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #9198 holding.
- Susquehanna International Group first reported a position in Compass Therapeutics in Q3 2022 and has held it in 14 quarters since.
- Susquehanna International Group's Compass Therapeutics position peaked at $2.56M in Q1 2023.
- 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.